Sector
PharmaceuticalsOpen
₹249.4Prev. Close
₹247.7Turnover(Lac.)
₹195.82Day's High
₹252Day's Low
₹247.0552 Week's High
₹39852 Week's Low
₹176.05Book Value
₹74.57Face Value
₹1Mkt Cap (₹ Cr.)
2,208.77P/E
32.24EPS
7.71Divi. Yield
0.16Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 37.05 | 8.47 | 8.47 | 8.47 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 533.45 | 486.63 | 485.3 | 419.76 |
Net Worth | 570.5 | 495.1 | 493.77 | 428.23 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 563.17 | 411.94 | 462.67 | 438.12 |
yoy growth (%) | 36.71 | -10.96 | 5.6 | -27.36 |
Raw materials | -339.99 | -246.36 | -289.89 | -295.84 |
As % of sales | 60.37 | 59.8 | 62.65 | 67.52 |
Employee costs | -41.17 | -39.35 | -32.8 | -26.92 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 91.11 | 50.75 | 60.34 | 41.58 |
Depreciation | -22.28 | -22.06 | -19.89 | -19.17 |
Tax paid | -30.15 | -18.06 | -19.89 | -5.96 |
Working capital | 60.27 | 35.89 | 36.48 | -52.78 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 36.71 | -10.96 | 5.6 | -27.36 |
Op profit growth | 51.54 | -14.37 | 24.78 | -16.14 |
EBIT growth | 62.43 | -16.96 | 32.87 | -22.21 |
Net profit growth | 86.5 | -19.19 | 13.58 | -14.46 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 782.75 | 709.26 | 522.05 | 519.87 | 563.18 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 782.75 | 709.26 | 522.05 | 519.87 | 563.18 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 6.22 | 4.46 | 4.91 | 5.2 | 3.45 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,669.8 | 93.52 | 4,00,520.99 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,616 | 79.48 | 1,75,574.28 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,513.8 | 25.39 | 1,22,186 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,321.5 | 20.61 | 1,10,263.53 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,222.5 | 57.29 | 1,09,167.44 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
P Ramesh Babu
Independent Director
P Sarath Kumar
Independent Director
Thummala Neelaveni
Independent Director
Shravan Kudaravalli
Independent Director
Sarvepalli Srinivas
Executive Director
Vamsi Krishna Potluri
Company Sec. & Compli. Officer
Thirumalesh Tumma
Independent Director
Trilok Potluri.
Non Executive Director
Sunkara Venkata Satya Shiva Prasad
Independent Director
G Suresh Kumar
Independent Director
Shanti Sree Bolleni
19 III Rd 71 Opp Bharatividya,
Bhavan Public Sch Jubilee Hill,
Telangana - 500096
Tel: 91-40-66288888
Website: http://www.smspharma.com
Email: [email protected]; [email protected];
1-2-285 Domalguda,
Hyderabad - 500 029
Tel: 91-040-27638111/4445
Website: www.aarthiconsultants.com
Email: [email protected]
Summary
SMS Pharmaceuticals Limited was incorporated in December, 1987. The company is engaged in the business of manufacturing of Active Pharma Ingredients and their intermediates. Apart from R &D Center at ...
Read More
Reports by SMS Pharmaceuticals Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.